Cullen Investment Group LTD. Invests $1.38 Million in Edwards Lifesciences Co. (NYSE:EW)

Cullen Investment Group LTD. purchased a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,088 shares of the medical research company's stock, valued at approximately $1,379,000.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $25,000. Compass Wealth Management LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $31,000. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $34,000. Jackson Grant Investment Advisers Inc. bought a new position in Edwards Lifesciences in the 3rd quarter valued at $38,000. Finally, Janiczek Wealth Management LLC grew its stake in Edwards Lifesciences by 108.6% in the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock valued at $40,000 after purchasing an additional 303 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on EW. OTR Global upgraded Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Truist Financial raised their target price on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, December 22nd. Citigroup raised their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Evercore ISI raised their price target on Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a report on Thursday, April 4th. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $91.73.

Edwards Lifesciences Trading Down 1.2 %

Shares of NYSE EW traded down $1.08 during midday trading on Monday, hitting $89.20. The company's stock had a trading volume of 2,845,478 shares, compared to its average volume of 3,906,282. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The business's 50 day moving average is $90.01 and its two-hundred day moving average is $77.79. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm has a market cap of $53.69 billion, a P/E ratio of 38.90, a price-to-earnings-growth ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the business posted $0.64 earnings per share. The company's revenue for the quarter was up 13.3% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Heisz Leslie Stone sold 7,056 shares of the business's stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the transaction, the director now owns 26,980 shares of the company's stock, valued at approximately $2,332,421. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.